<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/856A7EAA-C834-4DBE-8764-98C315C40614"><gtr:id>856A7EAA-C834-4DBE-8764-98C315C40614</gtr:id><gtr:name>Mario Negri Institute for Pharmacological Research</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/65CA66B5-6FE8-4FD7-9233-FBCF31BFD4B2"><gtr:id>65CA66B5-6FE8-4FD7-9233-FBCF31BFD4B2</gtr:id><gtr:name>Cornell University</gtr:name><gtr:address><gtr:line1>410 Thurston Ave</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/58930F3F-9B16-4DC2-833F-C72033E77A1E"><gtr:id>58930F3F-9B16-4DC2-833F-C72033E77A1E</gtr:id><gtr:name>Boston Children's Hospital</gtr:name><gtr:address><gtr:line1>Boston Childrens Hospital</gtr:line1><gtr:line2>Karp Building</gtr:line2><gtr:line3>9th floor, Rm 09210 1 Blackfan Circle</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Neuroscience Physiology and Pharmacology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/856A7EAA-C834-4DBE-8764-98C315C40614"><gtr:id>856A7EAA-C834-4DBE-8764-98C315C40614</gtr:id><gtr:name>Mario Negri Institute for Pharmacological Research</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/77558636-602F-416D-9BB4-73B783769BC3"><gtr:id>77558636-602F-416D-9BB4-73B783769BC3</gtr:id><gtr:name>Pfizer Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/65CA66B5-6FE8-4FD7-9233-FBCF31BFD4B2"><gtr:id>65CA66B5-6FE8-4FD7-9233-FBCF31BFD4B2</gtr:id><gtr:name>Cornell University</gtr:name><gtr:address><gtr:line1>410 Thurston Ave</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/58930F3F-9B16-4DC2-833F-C72033E77A1E"><gtr:id>58930F3F-9B16-4DC2-833F-C72033E77A1E</gtr:id><gtr:name>Boston Children's Hospital</gtr:name><gtr:address><gtr:line1>Boston Childrens Hospital</gtr:line1><gtr:line2>Karp Building</gtr:line2><gtr:line3>9th floor, Rm 09210 1 Blackfan Circle</gtr:line3><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A544B3F6-A07A-498E-9B7D-31D055013F58"><gtr:id>A544B3F6-A07A-498E-9B7D-31D055013F58</gtr:id><gtr:firstName>Annette</gtr:firstName><gtr:otherNames>Catherine</gtr:otherNames><gtr:surname>Dolphin</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700368"><gtr:id>ECB0CBBB-2F3C-484F-ABC7-821C83A0539A</gtr:id><gtr:title>The role of alpha2delta subunits in calcium channel function under physiological and pathological conditions</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700368</gtr:grantReference><gtr:abstractText>We are trying to understand the mechanism of action of a class of drugs that are used in the treatment of chronic pain.
The drugs, gabapentin, and its newer relative pregabalin, are used to alleviate various forms of chronic pain, including post-herpetic neuralgia and diabetic neuropathy, although they were originally developed for the treatment of certain types of epilepsy, for which they are also effective. 
Recent research has shown that these drugs have their effect by binding to a protein that makes up part of a calcium channel called the alpha2delta subunit. These calcium channels are present in all brain cells, and are essential for communication between them. In several animal models of chronic pain, the levels of alpha2delta subunits are found to increase in the damaged nerve cells.
In this study we now hope to understand, at the molecular level, how these alpha2delta subunits work, and how the binding of gabapentin to these proteins interferes with their function. To do this we will mainly use cells in tissue culture, but also where necessary, rodent models of disease.</gtr:abstractText><gtr:technicalSummary>Many anti-epileptic drugs inhibit voltage-gated cation channels, including calcium channels. However, gabapentin and its higher affinity analogue pregabalin are unique in this regard, because they bind to certain accessory alpha2delta subunits of calcium channels, rather than directly blocking the channel. These drugs are also effective in the treatment of neuropathic pain and allodynia following nerve damage. The alpha2delta subunits are involved in enhancing the number of calcium channels at the plasma membrane, and the main effect appears to be on trafficking. However, the mechanism of action of the gabapentinoid drugs is unknown at the molecular level. If this were better understood, it is possible that improved drugs would be forthcoming. Since these drugs also have other potential indications for the treatment of certain psychiatric disorders, such as anxiety, it is now very important to understand their mechanism of action. 
Now that we have available mutant alpha2delta-1 and alpha2delta-2 subunits that do not bind gabapentinoids, but remain partially functional, the potential to understand how these drugs produce their effect is much enhanced. These mutant alpha2deltas will be extensively utilised in this proposal.
 We will study the mechanism of trafficking of calcium channel alpha1 subunits by alpha2delta subunits, and the altered trafficking abilities of mutant alpha2delta-1 and -2 subunits that do not bind gabapentin. We will investigate the effect of gabapentinoid drugs on trafficking.
 We will also investigate the site and mechanisms of proteolytic processing of the alpha2delta subunits and the effect on function of blocking proteolytic processing by mutations and drugs. 
 It is known that alpha2delta-1 is up-regulated in DRGs in rat models of neuropathic pain. We will now investigate whether there is altered proteolytic processing of up-regulated alpha2delta subunits. 
 We will examine the effect of gabapentinoid drugs on calcium currents in cultured DRG neurons following over-expression of wild-type alpha2delta subunits or their gabapentin-resistant counterparts. 
 One section is directly relevant to human epilepsy as it involves the use of a rodent model of epilepsy in which rats have intermittent seizures. We will investigate whether there is up- or down- regulation of either alpha2delta-1 or -2 in epileptic foci. 
 Finally we will investigate the subcellular distribution of alpha2delta-2 in Purkinje cells, to gain further insight into the severe phenotype associated with its loss.
This research programme has the potential to elucidate further the mechanism of action both of alpha2delta subunits and of the gabapentinoid drugs which bind to them.</gtr:technicalSummary><gtr:fund><gtr:end>2011-04-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1029794</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Boston Children's Hospital</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Harvard collaboration</gtr:description><gtr:id>AE547689-B98B-431A-A83A-D8E40B4166E3</gtr:id><gtr:impact>none so far</gtr:impact><gtr:outcomeId>XwuHUNmPXgH-1</gtr:outcomeId><gtr:partnerContribution>supply of reagents and ideas</gtr:partnerContribution><gtr:piContribution>supply of reagents and ideas</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PhD studentship</gtr:description><gtr:id>C9161BBE-B4C0-4A30-BD00-7F489B9C607D</gtr:id><gtr:impact>PhD student completed 2 years</gtr:impact><gtr:outcomeId>BAF0731CB99-1</gtr:outcomeId><gtr:partnerContribution>PhD student just started</gtr:partnerContribution><gtr:piContribution>work on the drug pregabalin</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>translational grant</gtr:description><gtr:id>C50A6393-E69F-4B35-A9EB-4D31E1FE6F07</gtr:id><gtr:impact>MRC translational grant started in July 2009.</gtr:impact><gtr:outcomeId>E8FB3700B4A-1</gtr:outcomeId><gtr:partnerContribution>MRC translational grant will start in Jan 2009. GSK are giving support in kind.</gtr:partnerContribution><gtr:piContribution>work on alpha2delta splice variants</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Pfizer Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>consulancy</gtr:description><gtr:id>A37256BE-E140-4D23-BEF7-7C7184D81FD7</gtr:id><gtr:impact>as a result of this consultancy, I requested the PhD studentship from Pfizer</gtr:impact><gtr:outcomeId>9E4D12D8682-1</gtr:outcomeId><gtr:piContribution>one day paid consultancy</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cornell University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Graduate Field of Biochemistry</gtr:department><gtr:description>New York collaboration</gtr:description><gtr:id>6DA73C2A-E1C6-4381-8278-D346BAFF8EE9</gtr:id><gtr:impact>paper published</gtr:impact><gtr:outcomeId>rGwdZiZbr5i-1</gtr:outcomeId><gtr:partnerContribution>joint paper published further work ongoing</gtr:partnerContribution><gtr:piContribution>supply of reagents and ideas
experiments performed in my laboratory</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mario Negri Institute for Pharmacological Research</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>international collaborations</gtr:description><gtr:id>87E54A7A-50C6-4F6F-8719-E7283E40B5FF</gtr:id><gtr:impact>paper under revision
fellowship applications submitted</gtr:impact><gtr:outcomeId>AT2omE17P8D-1</gtr:outcomeId><gtr:partnerContribution>I am co-author on a joint paper
I am sponsor of a fellowship to continue the collaboration</gtr:partnerContribution><gtr:piContribution>supply reagents and ideas</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Mario Negri Institute for Pharmacological Research</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>GPI anchoring paper</gtr:description><gtr:id>AB45EA6C-F65F-437A-900D-15FB02E051D9</gtr:id><gtr:impact>new MRC grant</gtr:impact><gtr:outcomeId>CFDUnmyDLGF-1</gtr:outcomeId><gtr:partnerContribution>exchange of reagents. Joint paper in preparation</gtr:partnerContribution><gtr:piContribution>Discovery of GPI anchoring of alpha2delta subunits</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1029810</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Project Grant</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>7ECF5C03-5BE5-4F69-A296-349213916154</gtr:id><gtr:outcomeId>5350EDB68B80</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1153902</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>project grant</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>961CFA70-EE36-4AFB-BA84-8CC2E24FB3A8</gtr:id><gtr:outcomeId>pQrY9Yh2p2X0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>83568</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CASE PhD studentship</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>BC54668B-E212-4059-B6D1-5F9E3867691B</gtr:id><gtr:outcomeId>KB9JV2oAwSt0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>cell lines containing alpha2delta2, both -HA tagged and non-tagged</gtr:description><gtr:id>5E315A30-C19E-4924-A9C4-CD5617292949</gtr:id><gtr:impact>collaboration with Dr Roberto Chiesa</gtr:impact><gtr:outcomeId>E9C40D2C827</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>cell line</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5985CB8D-BBB2-42C7-897B-2680C5027FC5</gtr:id><gtr:title>Chronic pregabalin inhibits synaptic transmission between rat dorsal root ganglion and dorsal horn neurons in culture.</gtr:title><gtr:parentPublicationTitle>Channels (Austin, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/335ec006a30b9c5d839cd56ce8095689"><gtr:id>335ec006a30b9c5d839cd56ce8095689</gtr:id><gtr:otherNames>Hendrich J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1933-6950</gtr:issn><gtr:outcomeId>pm_13589_29_22627148</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F116F0A-57CC-4989-AF33-B75355FAE221</gtr:id><gtr:title>a2d-1 gene deletion affects somatosensory neuron function and delays mechanical hypersensitivity in response to peripheral nerve damage.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/10db95fd56b961dd90153cd3acb87a32"><gtr:id>10db95fd56b961dd90153cd3acb87a32</gtr:id><gtr:otherNames>Patel R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>pm_13589_29_24133248</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80BD1598-E54A-48AB-A43B-7DD1074BB9C5</gtr:id><gtr:title>The alpha2delta subunits of voltage-gated calcium channels form GPI-anchored proteins, a posttranslational modification essential for function.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fa3532ffe1fc272856d4b64bfe31e1b0"><gtr:id>fa3532ffe1fc272856d4b64bfe31e1b0</gtr:id><gtr:otherNames>Davies A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>F24A36A1EF5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B99797F9-CD2D-4AC7-A79E-1106A81345D5</gtr:id><gtr:title>The alpha2delta ligand gabapentin inhibits the Rab11-dependent recycling of the calcium channel subunit alpha2delta-2.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e37b03521cee86bffca810f1b86e8d44"><gtr:id>e37b03521cee86bffca810f1b86e8d44</gtr:id><gtr:otherNames>Tran-Van-Minh A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>HLhrf2qsQTJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>69771EE4-7294-473F-BC25-38D4F21F72BC</gtr:id><gtr:title>Pregabalin suppresses spinal neuronal hyperexcitability and visceral hypersensitivity in the absence of peripheral pathophysiology.</gtr:title><gtr:parentPublicationTitle>Anesthesiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5788d3295006bbaacc5a2870fe0f588b"><gtr:id>5788d3295006bbaacc5a2870fe0f588b</gtr:id><gtr:otherNames>Bannister K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0003-3022</gtr:issn><gtr:outcomeId>pm_13589_29_21602662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3BB8A225-08A8-4964-BFE2-0C491BFC8D75</gtr:id><gtr:title>Time course and specificity of the pharmacological disruption of the trafficking of voltage-gated calcium channels by gabapentin.</gtr:title><gtr:parentPublicationTitle>Channels (Austin, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e67812647a2b1b98af3ff7c886483183"><gtr:id>e67812647a2b1b98af3ff7c886483183</gtr:id><gtr:otherNames>Heblich F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1933-6950</gtr:issn><gtr:outcomeId>6CC566FE30A</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6AA031B6-B09B-48BF-BD99-BB64F2A906BD</gtr:id><gtr:title>Labelling of the 3D structure of the cardiac L-type voltage-gated calcium channel.</gtr:title><gtr:parentPublicationTitle>Channels (Austin, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0cbc1e0370d91ad0342a6084e9158b54"><gtr:id>0cbc1e0370d91ad0342a6084e9158b54</gtr:id><gtr:otherNames>Walsh CP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1933-6950</gtr:issn><gtr:outcomeId>53D4203FA56</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F63D7EE-39DC-460B-8B61-FFE8AAEA3B8C</gtr:id><gtr:title>a2d expression sets presynaptic calcium channel abundance and release probability.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/694816edcd105907b12e230a7b3296d8"><gtr:id>694816edcd105907b12e230a7b3296d8</gtr:id><gtr:otherNames>Hoppa MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>pm_13589_29_22678293</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3217DA3-071A-46CD-BF8C-DFDC5E042C9E</gtr:id><gtr:title>N terminus is key to the dominant negative suppression of Ca(V)2 calcium channels: implications for episodic ataxia type 2.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41e5eedcb2f50f624eb25d5e6b59751f"><gtr:id>41e5eedcb2f50f624eb25d5e6b59751f</gtr:id><gtr:otherNames>Page KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>CB14452B979</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB11B154-0453-4AFB-94ED-96DA3D197F88</gtr:id><gtr:title>Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/335ec006a30b9c5d839cd56ce8095689"><gtr:id>335ec006a30b9c5d839cd56ce8095689</gtr:id><gtr:otherNames>Hendrich J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>AE0794FE864</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4769FF67-58AA-4EA9-A544-0405580C6A25</gtr:id><gtr:title>Vesicular apparatus, including functional calcium channels, are present in developing rodent optic nerve axons and are required for normal node of Ranvier formation.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7dff1669ce639b5518ae58d08094e084"><gtr:id>7dff1669ce639b5518ae58d08094e084</gtr:id><gtr:otherNames>Alix JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn><gtr:outcomeId>3E760837624</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60C6A3BA-6BE1-4010-96C7-4C2071BDB109</gtr:id><gtr:title>Calcium currents are enhanced by a2d-1 lacking its membrane anchor.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f63eeedd8b411358f615b6a63ef007fe"><gtr:id>f63eeedd8b411358f615b6a63ef007fe</gtr:id><gtr:otherNames>Kadurin I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>doi_55f9849845b7c81f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A74DB334-6C84-40D1-97C8-EB1F4DB3F69E</gtr:id><gtr:title>The increased trafficking of the calcium channel subunit alpha2delta-1 to presynaptic terminals in neuropathic pain is inhibited by the alpha2delta ligand pregabalin.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/299a3711137bacbd0b1bc08a3f707f6e"><gtr:id>299a3711137bacbd0b1bc08a3f707f6e</gtr:id><gtr:otherNames>Bauer CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>A72760B6E48</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B86C84A-2243-4A4D-AEC7-BBA2853D6B3A</gtr:id><gtr:title>Calcium channel diversity: multiple roles of calcium channel subunits.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9631bc4bb22a3a0e999786bf8041fae5"><gtr:id>9631bc4bb22a3a0e999786bf8041fae5</gtr:id><gtr:otherNames>Dolphin AC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0959-4388</gtr:issn><gtr:outcomeId>3AAE2FA0E09</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35E8C9FF-1440-4DBA-A482-C427FCDF733D</gtr:id><gtr:title>Three-dimensional structure of CaV3.1: comparison with the cardiac L-type voltage-gated calcium channel monomer architecture.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0cbc1e0370d91ad0342a6084e9158b54"><gtr:id>0cbc1e0370d91ad0342a6084e9158b54</gtr:id><gtr:otherNames>Walsh CP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>B9DE7777985</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700368</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>